Deepa Rangachari
Distinguished in Lung Adenocarcinoma

Dr. Deepa Rangachari

Internal Medicine | Oncology
330 Brookline Avenue, Shapiro 9, 
Boston, MA 
On Staff At
Offers Telehealth
Distinguished in Lung Adenocarcinoma
330 Brookline Avenue, Shapiro 9, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Deepa Rangachari is an Internal Medicine specialist and an Oncologist in Boston, Massachusetts. Dr. Rangachari is rated as a Distinguished provider by MediFind in the treatment of Lung Adenocarcinoma. Her top areas of expertise are Lung Cancer, EGFR Positive Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Thymectomy.

Her clinical research consists of co-authoring 86 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 10 articles in the study of Lung Adenocarcinoma.

Graduate Institution
University Of Chicago, Pritzker School Of Medicine
Residency
Johns Hopkins Hospital
Specialties
Internal Medicine
Oncology
Licenses
Internal Medicine in MD
Board Certifications
American Board Of Internal Medicine
Fellowships
Johns Hopkins Hospital
Hospital Affiliations
Beth Israel Deaconess Hospital - Milton
Beth Israel Deaconess Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Senior Whole Health
  • MEDICARE-MEDICAID PLAN
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Shapiro 9, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Biomarkers of Response to Ipilimumab and Nivolumab as First-line Therapy for Metastatic Non-small Cell Lung Cancer (NSCLC): an Open-label, Single Arm Phase 2 Study
Biomarkers of Response to Ipilimumab and Nivolumab as First-line Therapy for Metastatic Non-small Cell Lung Cancer (NSCLC): an Open-label, Single Arm Phase 2 Study
Enrollment Status: Terminated
Publish Date: January 08, 2026
Intervention Type: Drug
Study Phase: Phase 2
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
Enrollment Status: Completed
Publish Date: October 21, 2024
Intervention Type: Drug, Device
Study Drug: Immune checkpoint inhibitors or docetaxel
Study Phase: Phase 3
Phase I/II Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
Phase I/II Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
Enrollment Status: Unknown
Publish Date: February 07, 2022
Intervention Type: Drug
Study Drugs: Olaparib, Temozolomide
Study Phase: Phase 1/Phase 2
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
Enrollment Status: Completed
Publish Date: August 05, 2021
Intervention Type: Drug
Study Phase: Phase 1
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
Enrollment Status: Completed
Publish Date: July 30, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

86 Total Publications

Modernizing Medical Education: Educational Strategies to Meet Emerging Needs in Hematology/Oncology.
Modernizing Medical Education: Educational Strategies to Meet Emerging Needs in Hematology/Oncology.
Journal: JCO oncology practice
Published: December 12, 2025
Similar Doctors
Elite in Lung Adenocarcinoma
Dr. Lecia Van Dam Sequist
Oncology
Elite in Lung Adenocarcinoma
Dr. Lecia Van Dam Sequist
Oncology

The General Hospital Corporation

40 2nd Ave, 
Waltham, MA 
 (9.0 miles away)
781-487-2900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lecia Van Dam Sequist is an Oncologist in Waltham, Massachusetts. Dr. Van Dam Sequist is rated as an Elite provider by MediFind in the treatment of Lung Adenocarcinoma. Her top areas of expertise are EGFR Positive Lung Cancer, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Tissue Biopsy.

Elite in Lung Adenocarcinoma
Dr. Bruce E. Johnson
Oncology
Elite in Lung Adenocarcinoma
Dr. Bruce E. Johnson
Oncology
450 Brookline Ave, Dana-farber Cancer Institute, 
Boston, MA 
 (0.2 miles away)
617-632-4790
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bruce Johnson is an Oncologist in Boston, Massachusetts. Dr. Johnson is rated as an Elite provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and EGFR Positive Lung Cancer. Dr. Johnson is currently accepting new patients.

Elite in Lung Adenocarcinoma
Dr. David J. Kwiatkowski
Oncology
Elite in Lung Adenocarcinoma
Dr. David J. Kwiatkowski
Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.2 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Kwiatkowski is an Oncologist in Boston, Massachusetts. Dr. Kwiatkowski is rated as an Elite provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Lung Adenocarcinoma, Lung Cancer, Mesothelioma, and Non-Small Cell Lung Cancer (NSCLC).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rangachari's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile